Sparton Corp. (SPA) is Trading Lower on Unusual Volume for January 01

Equities Staff |

Sparton Corp. (SPA) experienced unusually high volume on Jan. 01, as the stock lost 3.99% to a closing price of $19.99. The stock saw 98,397 shares trade hands over the course of the day on 804 trades. Given that the stock’s average daily volume over the last month has been 59,568 shares a day, this represents a pretty substantial spike over the norm.

Sparton Corp. has a P/B ratio of 1.65. It also has a P/E ratio of 15. The stock has traded between $29.49 and $18.67 over the last 52-weeks, its 50-day SMA is now $21.73, and its 200-day SMA $24.17.

Sparton Corp is a provider of design, development, and manufacturing services for complex electromechanical devices and engineered products. The Company serves the medical & biotechnology, military & aerospace and industrial & commercial markets.

Headquartered in Schaumburg, IL, Sparton Corp. has 1,823 employees and is currently under the leadership of CEO Cary B. Wood.

For a complete fundamental analysis analysis of Sparton Corp., check out’s Stock Valuation Analysis report for SPA. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.